Seroatlas · Human Serome Atlas

YARS1

Tyrosine--tRNA ligase, cytoplasmic

Also known as: SYYC_HUMAN, tyrRS, YARS, YRS, YTS

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P54577
Gene
YARS1
Ensembl
ENSG00000134684
Chromosome
1
Canonical length
528 aa
Protein class
Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
Subcellular location
Nuclear bodies,Cytosol
Quaternary structure
Homodimer

OverviewNCBI Gene

Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in tRNAs, aminoacyl-tRNA synthetases are thought to be among the first proteins that appeared in evolution. Tyrosyl-tRNA synthetase belongs to the class I tRNA synthetase family. Cytokine activities have also been observed for the human tyrosyl-tRNA synthetase, after it is split into two parts, an N-terminal fragment that harbors the catalytic site and a C-terminal fragment found only in the mammalian enzyme. The N-terminal fragment is an interleukin-8-like cytokine, whereas the released C-terminal fragment is an EMAP II-like cytokine. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

528 residues, UniProt reviewed canonical sequence.

>P54577|YARS1
     1  MGDAPSPEEK LHLITRNLQE VLGEEKLKEI LKERELKIYW GTATTGKPHV AYFVPMSKIA
    61  DFLKAGCEVT ILFADLHAYL DNMKAPWELL ELRVSYYENV IKAMLESIGV PLEKLKFIKG
   121  TDYQLSKEYT LDVYRLSSVV TQHDSKKAGA EVVKQVEHPL LSGLLYPGLQ ALDEEYLKVD
   181  AQFGGIDQRK IFTFAEKYLP ALGYSKRVHL MNPMVPGLTG SKMSSSEEES KIDLLDRKED
   241  VKKKLKKAFC EPGNVENNGV LSFIKHVLFP LKSEFVILRD EKWGGNKTYT AYVDLEKDFA
   301  AEVVHPGDLK NSVEVALNKL LDPIREKFNT PALKKLASAA YPDPSKQKPM AKGPAKNSEP
   361  EEVIPSRLDI RVGKIITVEK HPDADSLYVE KIDVGEAEPR TVVSGLVQFV PKEELQDRLV
   421  VVLCNLKPQK MRGVESQGML LCASIEGINR QVEPLDPPAG SAPGEHVFVK GYEKGQPDEE
   481  LKPKKKVFEK LQADFKISEE CIAQWKQTNF MTKLGSISCK SLKGGNIS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against YARS1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.27
Highest tissue expression
80 nTPM

Expression across tissuesHPA

Tissue

  • pancreas: 80 nTPM
  • basal ganglia: 62 nTPM
  • cerebral cortex: 62 nTPM
  • adrenal gland: 59 nTPM
  • skeletal muscle: 50 nTPM
  • tonsil: 47 nTPM

Single-cell type

  • megakaryocyte progenitors: 143 nCPM
  • cone photoreceptor cells: 141 nCPM
  • adrenal cortex cells: 137 nCPM
  • alveolar cells type 2: 128 nCPM
  • megakaryocyte-erythroid progenitors: 122 nCPM
  • nk-cells: 105 nCPM

Immune cell

  • NK-cell: 97 nTPM
  • gdT-cell: 58 nTPM
  • MAIT T-cell: 58 nTPM
  • basophil: 54 nTPM
  • memory CD8 T-cell: 54 nTPM
  • total PBMC: 51 nTPM

Brain region

  • basal ganglia: 75 nTPM
  • cerebral cortex: 71 nTPM
  • white matter: 70 nTPM
  • hypothalamus: 67 nTPM
  • thalamus: 61 nTPM
  • pons: 58 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about YARS1.

Disease | AllUniProt

Conditions YARS1 is implicated in, by any mechanism.

Disease | GeneticClinVar

15 pathogenic / likely-pathogenic of 656 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.62
gnomAD pLI
0
DepMap mean gene effect
-1.95
DepMap dependency class
pan

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of YARS1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads YARS1 as an antibody target. Whether an autoantibody or antibody against YARS1 could matter depends on whether native YARS1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

YARS1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label YARS1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/YARS1. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...